Advanced search

Online first
Guidelines / Expert consensus
Published online: 2024-12-19

open access

View PDF Download PDF file
Page views 12
Article views/downloads 8
Get Citation

Connect on Social Media

Connect on Social Media

Recommendations of Polish Adult Leukemia Group concerning diagnostics and treatment of polycythemia vera

Joanna Góra-Tybor1, Tomasz Sacha2, Maria Bieniaszewska3, Marta Sobas4, Krzysztof Lewandowski5, Patryk Sobieralski3, Olga Chyrko4, Aleksandra Gołos1

Abstract

Polycythemia vera (PV) belongs to a group of myeloproliferative neoplasms (MPN). The diagnosis of PV is based on the evaluation of complete blood count, bone marrow trephine biopsy samples, and molecular tests (confirmation of the JAK2 mutation). The main objectives of PV treatment include preventing thromboembolic complications, alleviating disease symptoms, and lowering the risk of transformation to myelofibrosis, acute myeloid leukemia and myelodysplastic syndrome. Taking into consideration the long-term course of PV, the choice of therapy should be based on an analysis of the risks resulting from the disease as well as from the adverse effects of the medication applied. In patients without risk factors (age < 60 years; no history of thrombosis), acetylsalicylic acid (ASA) and phlebotomy are recommended. Cytoreductive treatment is recommended in patients with poor tolerance of phlebotomy and with leukocytosis > 20 G/L, symptomatic progressive splenomegaly, significant thrombocytosis, persistent general symptoms of PV, and also in patients with significant cardiovascular risk. The therapy of choice in these patients is interferon α (IFNα). In a high-risk group of patients, (age ≥60 years and/or a history of thrombosis), treatment with ASA and phlebotomy should be accompanied by cytoreduction: hydroxyurea (HU) or, in the case of HU resistance/ intolerance, ruxolitinib (RUX) or IFNα. This paper discusses some aspects of the risk evaluation and summarizes the effectiveness of the available therapies, and also presents diagnostic and therapeutic recommendations for PV.

Keywords: polycythemia veramyeloproliferative neoplasmsdiagnosistreatment

Article available in PDF format

View PDF Download PDF file

References

  1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7): 1703–1719.
    CrossRefPubMed
  2. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11): 1200–1228.
    CrossRefPubMed
  3. Hultcrantz M, Ravn Landtblom A, Andréasson B, et al. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020; 287(4): 448–454.
    CrossRefPubMed
  4. Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019; 94(4): 599–610.
    CrossRefPubMed
  5. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013; 27(9): 1874–1881.
    CrossRefPubMed
  6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17): 1779–1790.
    CrossRefPubMed
  7. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037): 1144–1148.
    CrossRefPubMed
  8. Mathur A, Mo JR, Kraus M, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4): 387–397.
    CrossRefPubMed
  9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356(5): 459–468.
    CrossRefPubMed
  10. Tharakan S, Mascarenhas J, Tremblay D. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management. Leuk Lymphoma. 2024; 65(2): 158–167.
    CrossRefPubMed
  11. Sobieralski P, Wasąg B, Leszczyńska A, et al. The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype. Front Oncol. 2023; 13: 1224590.
    CrossRefPubMed
  12. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018; 93(12): 1474–1484.
    CrossRefPubMed
  13. Ronner L, Podoltsev N, Gotlib J, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020; 135(19): 1696–1703.
    CrossRefPubMed
  14. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5(11): e366.
    CrossRefPubMed
  15. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24(9): 1574–1579.
    CrossRefPubMed
  16. Barraco D, Cerquozzi S, Hanson CA, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017; 7(3): e538.
    CrossRefPubMed
  17. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012; 119(10): 2239–2241.
    CrossRefPubMed
  18. Tefferi A, Vannucchi AM. Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clin Proc. 2017; 92(8): 1283–1290.
    CrossRefPubMed
  19. Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020; 189(2): 291–302.
    CrossRefPubMed
  20. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016; 1(1): 21–30.
    CrossRefPubMed
  21. Barraco D, Cerquozzi S, Hanson CA, et al. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol. 2018; 182(3): 437–440.
    CrossRefPubMed
  22. Tang G, Hidalgo Lopez JE, Wang SaA, et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017; 102(9): 1511–1518.
    CrossRefPubMed
  23. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98(9): 1465–1487.
    CrossRefPubMed
  24. Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014; 124(19): 3021–3023.
    CrossRefPubMed
  25. Marchioli R, Finazzi G, Specchia G, et al. The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis. 2011; 2011: 794240.
    CrossRefPubMed
  26. Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017; 7(12): 662.
    CrossRefPubMed
  27. Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11): 1729–1737.
    CrossRefPubMed
  28. Barbui T, Vannucchi AM, Carobbio A, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017; 92(1): E5–E6.
    CrossRefPubMed
  29. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017; 92(1): 94–108.
    CrossRefPubMed
  30. Landolfi R, Marchioli R, Kutti J, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350(2): 114–124.
    CrossRefPubMed
  31. Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022; 9(4): e301–e311.
    CrossRefPubMed
  32. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22(11): 1945–1960.
    CrossRefPubMed
  33. European Assotiation of Preventive Cardiology E. Heart Score; Calculate the 10-year risk of fatal and non-fatal cardiovascular disease events of your patients 2021 [cited 2024 Aug 15]. Available from:. https://www.heartscore.org/en_GB.
  34. De Stefano V, Za T, Rossi E, et al. GIMEMA Chronic Myeloproliferative Neoplasms Working Party. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010; 85(2): 97–100.
    CrossRefPubMed
  35. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015; 126(4): 560–561.
    CrossRefPubMed
  36. Barbui T, Carobbio A, Ghirardi A, et al. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica. 2017; 102(6): e219–e221.
    CrossRefPubMed
  37. Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, et al. Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017; 102(1): 103–109.
    CrossRefPubMed
  38. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121(23): 4778–4781.
    CrossRefPubMed
  39. Kim SY, Bae SH, Bang SM, et al. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med. 2021; 36(1): 45–62.
    CrossRefPubMed
  40. Barbui T, Barosi G, Birgegard G, et al. European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6): 761–770.
    CrossRefPubMed
  41. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol. 2005; 42(4): 206–220.
    CrossRefPubMed
  42. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008; 93(3): 331–335.
    CrossRefPubMed
  43. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023; 41(19): 3534–3544.
    CrossRefPubMed
  44. Gisslinger H, Klade C, Georgiev P, et al. PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020; 7(3): e196–e208.
    CrossRefPubMed
  45. Jimenez K, Leitner F, Leitner A, et al. Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats. Haematologica. 2021; 106(3): 782–794.
    CrossRefPubMed
  46. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021; 8(3): e175–e184.
    CrossRefPubMed
  47. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997 Jan. ; 34(1): 17–23.
  48. Andréasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol. 1997; 59(3): 171–176.
    CrossRefPubMed
  49. Jimenez K, Khare V, Evstatiev R, et al. Increased expression of HIF2α during iron deficiency-associated megakaryocytic differentiation. J Thromb Haemost. 2015; 13(6): 1113–1127.
    CrossRefPubMed
  50. Crodel CC, Jentsch-Ullrich K, Reiser M, et al. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. J Cancer Res Clin Oncol. 2022; 148(10): 2693–2705.
    CrossRefPubMed
  51. Scherber RM, Geyer HL, Dueck AC, et al. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma. 2017; 58(6): 1481–1487.
    CrossRefPubMed
  52. Tobiasson M, Alyass B, Söderlund S, et al. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Med Oncol. 2010; 27(1): 105–107.
    CrossRefPubMed
  53. Kucine N. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults. Curr Hematol Malig Rep. 2020; 15(2): 141–148.
    CrossRefPubMed
  54. Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021; 96(3): 354–366.
    CrossRefPubMed
  55. Lebowa W, Ignatowicz A, Ząber J, et al. Current status of hydroxyurea in treatment of polycythemia vera. Acta Haematologica Polonica. 2024; 55(3): 145–150.
    CrossRef
  56. Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol. 2017; 92(11): 1131–1136.
    CrossRefPubMed
  57. Demuynck T, Verhoef G, Delforge M, et al. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. Ann Hematol. 2019; 98(6): 1421–1426.
    CrossRefPubMed
  58. Parasuraman S, DiBonaventura M, Reith K, et al. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2015; 5: 3.
    CrossRefPubMed
  59. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010; 148(6): 961–963.
    CrossRefPubMed
  60. Chiaranairungrot K, Kaewpreechawat K, Sajai C, et al. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance. Hematology. 2022; 27(1): 813–819.
    CrossRefPubMed
  61. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016; 172(5): 786–793.
    CrossRefPubMed
  62. Dingli D, Tefferi A. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep. 2006; 1(2): 69–74.
    CrossRefPubMed
  63. Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021; 35(9): 2592–2601.
    CrossRefPubMed
  64. Wang R, Shallis RM, Stempel JM, et al. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023; 7(5): 734–743.
    CrossRefPubMed
  65. Hansen IO, Sørensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2017; 98(1): 75–84.
    CrossRefPubMed
  66. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011; 117(18): 4706–4715.
    CrossRefPubMed
  67. Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022; 139(19): 2931–2941.
    CrossRefPubMed
  68. Vachhani P, Mascarenhas J, Bose P, et al. Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019; 33(12): 2974–2978.
    CrossRefPubMed
  69. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015; 126(15): 1762–1769.
    CrossRefPubMed
  70. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. NEJM Evid. 2023; 2(6): EVIDoa2200335.
    CrossRefPubMed
  71. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5): 426–435.
    CrossRefPubMed
  72. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017; 18(1): 88–99.
    CrossRefPubMed
  73. Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017; 176(1): 76–85.
    CrossRefPubMed
  74. Cardiovascular risk collaboration of ESC swg. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1. ; 42(25): 2439–2454.
  75. Heidel FH, Al-Ali HK, Hirt C, et al. Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO). Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia. 2018; 32(9): 2085–2087.
    CrossRefPubMed
  76. European Medicine Agency E. Besremi prescribing information 2021 [cited 2024 Aug 22]. Available from: . https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf.
  77. Barbui T, Passamonti F, Accorsi P, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia. 2018; 32(9): 2077–2081.
    CrossRefPubMed
  78. Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010; 116(8): 1205–10; quiz 1387.
    CrossRefPubMed
  79. Falanga A, Marchetti M, Schieppati F. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. Hamostaseologie. 2021; 41(1): 48–57.
    CrossRefPubMed
  80. McMullin MFF, Mead AJ, Ali S, et al. British Society for Haematology Guideline. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. Br J Haematol. 2019; 184(2): 161–175.
    CrossRefPubMed
  81. Duerden M, O’Flynn N, Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. British Journal of General Practice. 2015; 65(636): 378–380.
    CrossRef
  82. NICE) NIfHaCE. National Institute for Health and Care Excellence: Clinical Guidelines Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: National Institute for Health and Care Excellence. (NICE): 2023.
  83. Schieppati F, Falanga A. Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN? Hematology Am Soc Hematol Educ Program. 2021; 2021(1): 448–452.
    CrossRefPubMed
  84. Weronska A, Papuga-Szela E, Broniatowska E, et al. Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. J Cardiovasc Pharmacol. 2021; 78(5): e743–e748.
    CrossRefPubMed
  85. Serrao A, Breccia M, Napolitano M, et al. A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms. Am J Hematol. 2020; 95(12): E329–E332.
    CrossRefPubMed
  86. Barbui T, De Stefano V, Carobbio A, et al. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia. 2021; 35(10): 2989–2993.
    CrossRefPubMed
  87. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122(13): 2176–2184.
    CrossRefPubMed
  88. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024; 99(4): 697–718.
    CrossRefPubMed
  89. Wille K, Brouka M, Bernhardt J, et al. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET. Hemasphere. 2023; 7(5): e882.
    CrossRefPubMed
  90. Landtblom AR, Andersson TML, Johansson ALV, et al. Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden. Leukemia. 2022; 36(10): 2461–2467.
    CrossRefPubMed
  91. Robinson S, Ragheb M, Harrison C. How I treat myeloproliferative neoplasms in pregnancy. Blood. 2024; 143(9): 777–785.
    CrossRefPubMed
  92. Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012; 33(3): 265–268.
    CrossRefPubMed
  93. Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica. 2016; 101(5): e182–e184.
    CrossRefPubMed
  94. Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018; 11(9): 697–706.
    CrossRefPubMed
  95. Vannucchi AM, Barbui T, Cervantes F, et al. ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v85–v99.
    CrossRefPubMed
  96. Mesa RA, Jamieson C, Bhatia R, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017; 15(10): 1193–1207.
    CrossRefPubMed
  97. Sobas M, Kiladjian JJ, Beauverd Y, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022; 6(17): 5171–5183.
    CrossRefPubMed
  98. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost. 2006; 32(4 Pt 2): 422–429.
    CrossRefPubMed
  99. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005; 129(3): 293–306.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note